



EPICA **DIPG**

European Paediatric Immunotherapy Trial
with Combinatory ATMPs for DIPG

**ADVANCING
INNOVATIVE
IMMUNOTHERAPY
RESEARCH
FOR CHILDREN
WITH DIPG**

epica-dipg.eu

WHY EPICA **DIPG**?



- Every year, more than 300 children in Europe are diagnosed with DIPG, **one of the most aggressive paediatric brain tumours.**
- Treatment options remain extremely limited. **New approaches are urgently needed.**
- **Evidence is necessary** before a more advanced clinical evaluation can take place.

**EPICA-DIPG is designed
to generate multiple forms of evidence
to guide future research**

THE EPICADIPG APPROACH



Three connected areas form **one research framework**.

01 Clinical research

A research-stage immunotherapy strategy evaluated in a Phase I study whose primary purpose is to assess safety.

02 Companion diagnostics

Developing approaches to monitor immune response and disease burden during the study.

03 Manufacturing and delivery

Testing how complex advanced therapies can be manufactured and delivered across participating centres.

WHAT IS **EPICA**DIPG DESIGNED TO EVALUATE?



- **Evidence on safety and feasibility** in a first-in-human setting.
- **Biological and immunological knowledge** about how the approach behaves.
- Learning from the **development of companion diagnostic approaches**.
- Operational knowledge about **manufacturing and delivery across centres**.
- **Evidence that may inform** future clinical and translational research.

EPICA-DIPG is not designed to demonstrate clinical benefit at this stage.

EPICADIPG AT A GLANCE



DURATION September 2026
to August 2031 (60 months)

PARTICIPANTS 11 organisations

COUNTRIES Spain · Italy · The Netherlands

EU CONTRIBUTION Approximately €8 million

COORDINATOR Fundació Privada
per a la Recerca i la Docència
Sant Joan de Déu

SJD Sant Joan de Déu
Institut de Recerca [®]



EPICA **DIPG**

**CONNECTS CLINICAL
RESEARCH, BIOLOGICAL
MONITORING, AND
CROSS-CENTRE DELIVERY
TO GENERATE EVIDENCE
FOR FUTURE
DIPG RESEARCH**

epica-dipg.eu



Funded by
the European Union

EPICA-DIPG has received funding from the European Union's Horizon Europe research and innovation programme under grant agreement No 101286703. Views and opinions expressed are, however, those of the author(s) only and do not necessarily reflect those of the European Union or the European Health and Digital Executive Agency (HaDEA). Neither the European Union nor the granting authority can be held responsible for them.